Overview

A Phase 1, Randomized, Double-Blind, First-In-Human, Dose Escalation Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Status:
Not yet recruiting

Trial end date:
2023-01-15

Target enrollment:

Participant gender:

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.

Phase:

Phase 1

Details

Lead Sponsor:

SNIPR Biome Aps.

Collaborators:

Biomedical Advanced Research and Development Authority
Wellcome Trust